Delisting riskPopularity #3,733
BIVI · NASDAQ · Biotechnology

BioVie (BIVI)

Develops bezisterim and continuous-infusion terlipressin therapies.

$1.63
After hours−0.01 (−0.31%)
At close$1.64(+0.31%)
  1. Dow falls as US strikes Iran, rate-hike bets jump

    Proactive Investors - Finance

  2. BioVie: Long COVID trial fully enrolled – ICYMI

    Proactive Investors - Finance